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Abstract
The recently approved interferon-free DAA (direct antiviral agents) regimens have shown not only to be effective in
terms of sustained virological response (SVR) rates (> 90%) but also well tolerated in most hepatitis C virus (HCV)
infected patients. Nevertheless HCV genotypes are different and only a small percentage of trials consider genotype
4 (GT4), which was associated with lower rates of SVR compared with other genotypes before the arrival of the
DAA’s. In this review, we discuss the efficacy of DAA therapy in GT4 HCV infection with specific reference to more
recent studies, including those conducted in a ‘field-practice’ scenario. Overall, DAA-based regimens appear more
effective also in the poorly-explored setting of patients with HCV GT4 infection. Despite an overall limited number
of patients was evaluated, favorable results are being derived from studies on ombitasvir/paritaprevir/ritonavir,
sofosbuvir and velpatasvir, whether or not in association with voxilaprevir, and with the new combined therapy
glecaprevir + pibentasvir.
Introduction
The introduction of direct antiviral agents (DAAs) in
clinical practice has undoubtedly represented a landmark
advance in the treatment of hepatitis C virus infection
(HCV) [1, 2]. With these therapies, the wide majority
(90–95%) of HCV-infected patients can now be success-
fully cured [2, 3]. Less attention was paid to genotype 4
(GT4) HCV in clinical trials and field-practice studies
compared with other genotypes [4]. Current estimates
state that this GT accounts for 13% of all HCV infections
[5]. The bulk of the GT4 infection is found in the Middle
East, Northern Africa and Sub-Saharan Africa, with 93%
of HCV patients in Egypt being infected by this genotype
[5, 6]. In Europe, prevalence of GT4 infection is more
variable (up to 16% in Italy in HIV co-infected patients,
8% in Spain, 14% in Belgium); however, migration flows
from Northern Africa are likely to increase the prevalence
of GT4 HCV infection in the next years [5, 7]. Import-
antly, GT4 is a historically difficult to treat genotype, and
a trend towards lower rates of sustained virological
response (SVR) in GT4 has been signaled also with DAA
treatment [1]. A recent excellent review by Hathorn and
Elsharkawy has extensively discussed current evidence on
the treatment of GT4 HCV infection in the DAA era, with
a focus on clinical trials [4]. However, the advancement of
clinical research in HCV treatments proceeds at such a
high pace that continuous update is necessary [4]. In par-
ticular, information on patients with renal disease - who
often present HCV infection and who are particularly
challenging to treat- appears required.
In this review, we discuss the efficacy of DAA therapy in
GT4 HCV infection with specific reference to more recent
studies, including those conducted in a ‘field-practice’
scenario.
Methods
Papers for consideration in the present review were re-
trieved via a PubMed query, using “DAA AND HCV
AND genotype 4” as keywords. Research was last updated
on 22nd Sept 2017. No other limitations were applied. In
total, 247 papers met these criteria. Papers were then se-
lected for inclusion in the present manuscript according
to their relevance for the topic, as judged by the Authors.
When possible, studies with specific reference to GT4
infection were selected. Overall, 17 clinical trials (one in
patients undergoing hemodialysis), 17 ‘field-practice’ expe-
riences (two of which on patients with renal disease) and
one meta-analysis of real-world data were reported
[Table 1].
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Table 1 Key results of the clinical trials included in the present analysis
Clinical trial or field
experience
n° of patients with G4-infection Treatment SVR rate in GT4 patients
Ruane 2015 [8] 34 SOF + RBV 68–93%
Feld 2015 [9] 116 SOF/VEL 100%
Curry 2015 [10] 8 SOF/VEL 100%
Gane 2016 [11] 17 SOF/VEL + VOX 58%
Bourliere 2017 [12] 41 (POLARIS-1 + POLARIS-4) SOF/VEL + VOX 97%
Colombo 2017 [13] 10 SOF/LDV 100%
Kholi 2015 [14] 21 SOF/LDV 95%
Buti 2017 [15] 40 SMV/SOF 100%
El Raziky 2017 [16] 63 SMV/SOF 92%
Kwo 2017 [17] 37 EBR + GZR 89%
Waked [18] 160 OBV/PTV/R/RBV 93–94%
Hézode 2015 [19] 135 OBV/PTV/r ± RBV 100% with RBV, 91% without RBV
Forns [20] 16 GLI/PIB 100%
Kwo [42] 22(SURVEYOR-I and SURVEYOR-II) GLI/ PIB 100%
Asselah [21] SURVEYOR-II Part 4, ENDURANCE-4
and ENDURANCE-2)
GLI/ PIB 93% 8 week treatment
99% 12 week treatment
Yakoot [22] 120 (randomized 60 in 12 weeks
regimen and 60 in response tailored
regimen)
SOF + DAC 96.7% in the fixed regimen
98.4% in the response tailored regimen
El-Khayat [23] 551 cirrotic patients (432 naïve, 119
treatment experienced)
SOF + DAC + RBV 92%in naïve
87% in experienced
Willemse [24] 53 (naïve and IFN experienced) SOF + SIM 92%
Degre [25] 87, IFN experienced SOF + SIM ± RBV 87.4%
Elsharkawy 2017 [26] 8742 (F3)
5667 (F3)
SOF/peg/IFN-RBV
SOF/RBV
94%
79%
Asselah 2017 [27] 67 naïve, F0-F2 SIM + PEG IFN 97%
Ioannou [28] 135 (two arm: 104, 31) SOF/LDV ± RBV and OBV/PTV/r ± RBV 89.6%
Crespo [29] 152 (two arm:130 and 122) SOF/LDV ± RBV and OBV/PTV/r ± RBV 95.4 and 96.2%
Welzel [30] 53 OBV/PTV/r ± RBV 100%
Perello [31] 87 (73% cirrhosis, 35% treatment naïve) OBV/PTV/r ± RBV 100%
Petta 2017 [32] 17 OBV/PTV/r ± RBV 94%
Wedemeyer 2017 [33] 112, 19 cirrhosis OBV/PTV/r ± RBV 96,5%
Komatsu [34] 26 EBR + GZR 100%
Maria 2017 [35] 7 SOF ± SIM or DAC or LDV ± RBV 100%
Hezode 2016 [36] 215 SOF + DAC 91%
Babatin 2017 [37] 40
35% cirrhotic; treatment-experienced
52.5%
SOF + DAC
+ RBV
100%
Abad 2017 [38] 35 OBV/PTV/r 100%
Ponziani 2017 [46] 8 OBV/PTV/r 100%
Manns 2016 [43] 37 SOF/LDV + RBV 81%
GT4 HCV Genotype 4, SOF sofosbuvir, VEL velpatasvir, VOXvoxilaprevir, LDV ledipasvir, SIM simeprevir, RBV ribavirin, EBR elbasvir, GZR grazoprevir, OBV ombitasvir,
PTV paritaprevir, GLI glicaprevir, PIB pibrentasvir, DAC daclatasvir
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Clinical trials
Sofosbuvir
In an open-label study at single center, 60 patients were
enrolled and completed treatment with Sofosbuvir plus
ribavirin for 12 weeks (31 patients) or 24 weeks (29 pa-
tients). SVR 12 was achieved by 21 of the 31 patients
(68%) receiving 12 weeks of treatment, and by 27 of 29
patients (93%) receiving 24 weeks of treatment [8].
Sofosbuvir/velpatasvir
In clinical trials, the association of sofosbuvir and velpa-
tasvir (SOF/VEL) showed promising results. In a phase
3, double-blind, placebo-controlled study, 116 patients
with GT4 infection (52/116 treatment experienced, 27/
116 cirrhotic) were treated with such association, reach-
ing 100% SVR [9]. The same association was also investi-
gated in 267 patients with decompensated cirrhosis in
the ASTRAL-4 study [10]. In this difficult-to-treat popu-
lation, serious adverse events occurred in 19% of pa-
tients who received 12 weeks of SOF/VEL, 16% of those
who received 12 weeks of SOF/VEL plus ribavirin (RBV),
and 18% of those who received 24 weeks of SOF/VEL.
Only eight patients infected with GT4 have been
included in the study and all achieved SVR.
Sofosbuvir/velpatasvir/voxilaprevir
In a multicenter, phase II study on sofosbuvir, velpatasvir
and voxilaprevir (SOF/VEL/VOX), Gane et al. have inves-
tigated the optimal regimen for patients with GT1, 2, 3, 4
or 6 infections [11]. In total, 128 patients were enrolled; of
these, 17 presented GT4 infection (10 treatment-naïve
and 7 with prior therapy). In total, only 7 patients experi-
enced a virological failure, of whom 3 were GT4 infected.
All three patients were treatment-naïve, two were non-cir-
rhotic patients treated for 6 weeks, while the third was a
cirrhotic patient treated for 8 weeks. Additional data come
from the POLARIS-1 and POLARIS-4 studies, in which
22 and 19 patients infected with HCV GT4 have been in-
cluded, respectively, and were treated with SOF/VEL/
VOX [12]. All patients had been previously treated with a
DAA-containing regimen; 21/22 subjects in POLARIS-1
and 19/19 in POLARIS-4 achieved SVR. The only treat-
ment failure, in POLARIS-1, occurred in a cirrhotic pa-
tient who had been previously treated with SOF and
ledipasvir (SOF/LDV) for 12 weeks in 2015, while no
other patient with GT4 experienced treatment failure with
this triple drug regimen.
Sofosbuvir/ledipasvir
In an international, randomized, phase II, open-label
study, the safety and efficacy of SOF/LDV in fixed-dose
combination tablet, for 12 or 24 weeks were compared in
114 kidney transplant recipients (69% treatment-naïve)
with GT1 (91%) or GT4 infection (9%) [13]. Remarkably,
all patients, regardless of treatment duration, achieved
SVR12. Serious adverse events were reported in 13 pa-
tients (11%), and one patient permanently discontinued
treatment due to an adverse event (syncope). In a
proof-of-concept, single-center, open-label, phase 2a trial,
SOF/LDV was also studied exclusively in patients infected
with GT4 [14]. In this study, only 21 patients have been
included, but 20 of them achieved SVR after 12 weeks of
SOF/LDV (95%), including seven patients with cirrhosis,
while the only patient who failed achieving SVR was
non-adherent to treatment. No patients discontinued
therapy due to adverse events and no grade 3 or 4 adverse
events related to study medications were reported.
Simeprevir
Two recently published clinical trials investigated the effi-
cacy of simeprevir (SMV) + SOF in GT4 patients: PLUTO
and OSIRIS studies [15, 16]. The PLUTO study is a phase
III open-label trial, that investigated the efficacy of
12-weeks treatment with SMV+ SOF in GT4-infected pa-
tients either naïve or experienced to antiviral therapy [15].
In total, 40 patients were evaluated; of these, 27 (68%)
were treatment-experienced and 7 (18%) had compensated
cirrhosis. Noteworthy, all patients achieved SVR12, while
adverse events, all of mild-to-moderate intensity, were
reported in 20/40 (50%) of patients. The other recently
published trial evaluating the efficacy and safety of SMV +
SOF was the OSIRIS study, in which GT4 HCV-infected
patients with F0-F4 fibrosis were treated for 8 or 12 weeks
[16]. In total, 63 patients (33 treatment-naïve and 30
Peg-IFN/RBV-experienced) were randomly assigned to
receive either 8 weeks (Group A1, n = 20) or 12 weeks
(Group A2, n = 20) of treatment. Patients with compen-
sated cirrhosis (METAVIR F4) received 12 weeks of treat-
ment (Group B, n = 23). Overall, 92% of patients achieved
SVR12; corresponding figures were 75% in Group A1 and
100% in both groups A2 and B. The five patients who did
not achieve SVR12 experienced viral relapse during the
first 32 days following treatment and were all prior
Peg-IFN/RBV null responders. No patients discontinued
due to treatment-emergent adverse events.
Elbasvir and grazoprevir
In a phase III, randomized, controlled, open-label trial, the
effects of 12 or 16 weeks of treatment with elbasvir (EBR)
and grazoprevir (GZR) in fixed-dose combination tablet,
with or without twice-daily RBV, were evaluated in 420
treatment-experienced patients with GT1, GT4 or GT6
infection [17]. Patients were randomly assigned (1:1:1:1) to
treatment with EBR +GZR once daily, with or without
twice-daily RBV, for 12 or 16weeks. Thirty-seven patients
were GT4 (47% cirrhotic). Of them, 24 received 12 week-
treatment (9 without and 15 with RBV) and 13 were
treated for 16 weeks (5 without and 8 with RBV). The
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global proportion of SVR12 in patients infected with GT4
was 88.9%, with the highest rate of failure, 12.5%, in pa-
tients treated for 12 weeks without RBV and the lowest, 0%,
in patients treated for 16 weeks with RBV.
Ombitasvir/paritaprevir/ritonavir
The efficacy of OBV/PTV/r in GT4 have also been ex-
plored in a multicentre phase 2b, randomised, open-label
combination trial (PEARL-I), in which 135 patients with
GT4 (49/135 treatment experienced) have been included
and randomly assigned to receive once-daily OBV/PTV/r
for 12 weeks with or without RBV [18]. SVR was achieved
by 100% of patients treated with the addition of RBV and
by 91% of those treated without. Only three treatment-
naive patients who received OBV/PTV/r without RBV ex-
perienced virological failure, and they were all infected
with GT4. One patient in OBV/PTV/r experienced an
aspartate aminotranferase (AST) elevation of grade ≥ 3
and three patients in OBV/PTV/r + RBV experienced a
bilirubin elevation of grade 3.
In the AGATHE-II a phase 3, open label, 182 patients
with GT4 were screened, of whom 160 were eligible for
inclusion; SVR was achieved by 94% (94/100) of patients
without cirrhosis, and 97% (30/31) patients with cirrhosis
treated for 24 weeks; Instead SVR was achieved by 93%
(27/29) of patients with cirrhosis treated for 24 weeks [19].
Glecaprevir/pibrentasvir
The recently approved once-daily, ribavirin-free, DAA
regimen of glecaprevir co-formulated with pibrentasvir, has
been studied for pangenotypic HCV treatment. In the
phase 3 study EXPEDITION-1, 16 GT4 infected patients
with compensated cirrhosis had 100% sustained response
after 12 weeks of treatment [20], and the same (100% SVR)
was also found in SURVEYOR-I and SURVEYOR-II phase
II, dose-ranging trials, despite the presence of baseline
polymorphisms, in 22 GT4 infected patients [20]. In 3 sep-
arate phase 3 trials performed in patients without cirrhosis,
(SURVEYOR-II Part 4, ENDURANCE-4 and ENDURA
NCE-2), 43/46 GT4 patients treated for 8 weeks and 75/76
patients treated for 12 weeks achieved SVR [21].
Daclatasvir
A recent paper reports a successful experience in treating
patients with GT4 chronic infection with generic formula-
tions of SOF and daclatasvir (DAC) [22]; in this open-label
randomized non-inferiority study, in which all enrolled pa-
tients were non-cirrhotic and had GT4 chronic infection,
two different schedules of treatment were compared. Pa-
tients were divided into two groups: a fixed duration group,
in which all patients received 12weeks of therapy, and a
virological guided response group, in which patients could
receive either 8 or 12 weeks of therapy, based on a viro-
logical response. Indeed, patients were treated for 8 weeks
only if they achieved a very rapid virological response
(vRVR), defined as an undetectable viral load after 2 weeks
of treatment (patients not reaching vRVR were continuing
treatment at 12 weeks). This trial showed a SVR12 of
96.67% (ITT) in the group with a fixed duration and of
98.33% in the virological guided response group. No major
adverse events were observed, while a shorter treatment
period could increase adherence, reduce the drug exposure
and optimize resource use, reducing the cost of about one
third [23]. A second multicentre, open-label trial, con-
ducted exclusively in GT4 patients, describes the experi-
ence with SOF and DAC in patients with more advanced
stages of disease. Five hundred fifty-one cirrhotic patients
(468 Child A; 83 Child B) were enrolled to receive SOF and
DAC plus weight-adjusted RBV for 12 weeks. Among them,
432 were naïve to IFN-treatment, whereas 119 were
treatment-experienced. In the intention to treat analysis,
the overall 12 week SVR rate was 92% in naïve patients, but
lower, 68%, in patients presenting more than one negative
predictor of response (treatment experienced and Child B
cirrhotic). The corresponding figures in per protocol
analysis were 94 and 79%. [23].
‘Field-practice’ experiences
Simeprevir
In a multicenter, ‘field-practice’, retrospective study, Will-
emse et al. have specifically assessed the effectiveness of
treatment with SOF and SMV, with or without RBV, in a
cohort of GT4 HCV patients [24]. A total of 53 patients,
either naïve or experienced, were included. SVR rate was
92% (49/53). All four failures showed virological relapse
and were not treated with RBV. In another experience,
conducted in Belgium, Degrè et al. evaluated 87
GT4-infected treatment-naïve or IFN-experienced
patients treated with SOF and SMV with or without
RBV (41% had severe fibrosis, and 59% cirrhosis) [25].
The overall SVR12 rate was 87.4%, while patients treated
with and without RBV had rates of 87.9 and 87%,
respectively. On the other hand, patients with advanced
fibrosis and patients with cirrhosis had SVR12 rates of
94.4 and 82.4%, respectively. SVR12 rates in treatment-
naïve patients and in INF-experienced patients were 78.9
and 89.7%. In most cases, treatment failure occurred in
patients with cirrhosis and severe disease. The treatment
was well tolerated and no patient discontinued treat-
ment due to adverse events.
In a multicenter study, Asselah et al. investigated the ef-
ficacy and safety of 12-week SMV plus peg-IFN/RBV in
67 treatment-naïve patients with GT4 infection and F0-F2
fibrosis [26]. Patients with early virologic response (HCV
RNA < 25 IU/mL) at Week 2 and HCV RNA undetectable
at weeks 4 and 8 were eligible to stop all treatment at the
end of week 12 (n = 34), otherwise Peg-IFN/RBV therapy
was continued to week 24. All patients in the 12-week
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group showed undetectable HCV RNA at end of treat-
ment, and 97% (33/34) achieved SVR12. No new safety
signals were reported.
Sofosbuvir
A large National Treatment Programme was launched in
Egypt practice in October 2014. Patients who were eli-
gible for treatment were classified according to their eligi-
bility for interferon therapy: Group 1 were treated with
triple therapy for 12 weeks and Group 2 (interferon ineli-
gible) were treated with Sofosbuvir and ribavirin for 24
weeks. The study analysed the data from the first 14,409
patients who completed follow-up to 12 weeks post HCV
treatment. SVR12 rates were 94% and 78.7 in Group 1
and Group 2, respectively [27].
Sofosbuvir/ledipasvir
A large ‘field-practice’ retrospective analysis (N = 17,487)
of the Veterans Affairs National Health Care System has
evaluated the effectiveness of SOF/LDV and OBV/PTV/r
in the treatment of 135 patients with HCV GT4 infection
[28]. Of them, 104 received SOF/LDV ± RBV and 31
OBV/PTV/r ± RBV. Overall, SVR12 rate was 89.6% (95%
CI 82.8–93.9), with a higher incidence in treatment-expe-
rienced subjects (93.5%). Interestingly, 96.4% of
GT4-infected, OBV/PTV/r-treated patients achieved
SVR12, compared with 87.6% of those receiving SOF/
LDV. A smaller, but prospective, Spanish cohort study
confirmed the above-mentioned findings [29]. In more de-
tails, GT4-infected patients treated with OBV/PTV/r +
RBV (n = 122) or SOF/LDV ± RBV (n = 130) were evalu-
ated. SVR12 rates were 96.2% with OBV/PTV/r + RBV
and 95.4% with SOF/LDV ± RBV. In cirrhotic patients,
SVR12 was 91.2% with OBV/PTV/r + RBV and 93.2% with
SOF/LDV ± RBV. Rates of severe adverse events and asso-
ciated discontinuations were 5.7 and 2.5% in the OBV/
PTV/r sub-cohort, respectively and 4.6 and 0.8% in the
SOF/LDV sub-cohort, respectively; in most cases, these
events were likely due to RBV administration (e.g.,
anemia).
Ombitasvir/paritaprevir/ritonavir
In addition to the above-mentioned experiences (see
previous paragraph, [25–28]), in another ‘field-practice’
study, from the German Hepatitis C Registry, Welzel et
al. investigated the effectiveness of OBV/PTV/r ± RBV in
53 patients infected by GT4: all of them achieved SVR12
[29]. Similar findings were reported in a Spanish early
access program, the effectiveness and safety of OBV/
PTV/r was retrospectively investigated [30]. In total,
291, either infected 69.8% by GT1 or 30.2% by GT4
(73% with cirrhosis, 35% treatment-naïve) were evalu-
ated. The rate of SVR12 was 96.2% for GT1 and 100%
for GT4, with no statistical difference according to viral
genotype. Thirty patients (10.3%) experienced serious
adverse events, leading to discontinuation in six cases,
once again due in most cases to RBV treatment. Al-
though the number of GT4 patients was small, a
prospective observational study, with collected data from
ABACUS compassionate-use program, has investigated
the use of OBV/PTV/r with dasabuvir plus RBV for GT1
and OBV/PTV/r plus RBV for GT4 infection (24 weeks
of treatment) in patients with cirrhosis at high risk of
decompensation, while approval of these regimens was
pending in Italy [31]. In total, 762 patients were evalu-
ated. Of them, only 17 had GT4 and 16 (94%) achieved
SVR. The number of patients infected by GT4 was too
low to allow a sub-group analysis, but, in the global
population of this study, logistic regression analyses
identified that bilirubin concentrations of less than 2
mg/dL were associated with SVR12 (odds ratio [OR]
4.76 [95% CI 1.83–12.3]; p = 0·001. Overall, the SVR rate
was 96%; 23% of patients experienced adverse events,
with asthenia being the most commonly reported (5%).
A meta-analysis of real world data of a total of 5158 pa-
tients (5046 with HCV GT1 and 112 GT4 infection),
treated with OBV/PTV/r ±DSV ±RBV across 25 primary
publications, showed an overall SVR of 96.8% (95% CI, 96.3
97.3) [32]. Cohort data included fewer patients with GT4
infection and cirrhosis, and breakdown data was available
for 19 of them; 99% (95%CI, 82.3–100) of them achieved
SVR. The rate of response was similar for non-cirrhotic
patients with GT4 infection, as 100% (51/51) achieved SVR.
Elbasvir/gazoprevir
The independent analysis of the US Food and Drug Ad-
ministration has shown that 100% (26 out of 26) patients
with HCV GT4 infection and NS5A polymorphisms
who received EBR + GZR with or without RBV achieved
SVR12 [33].
Daclatasvir
In a Swedish experience, the outcome of IFN-free treat-
ment for HCV relapse after liver transplantation has
been documented [34]. In total, 93 patients with HCV
relapse after liver transplantation received SOF-based
treatment either in combination or not with SMV, DAC
or LDV with or without RBV. Of these, 7 patients were
infected by GT4 HCV, and all of them achieved SVR12.
Good results were also recorded in the ATU French
cohort, composed by 176 GT4 patients treated with SOF
and DAC. All the patients enrolled had advanced stages
of liver fibrosis and no other treatment option, at the
time of the study. The overall SVR 12 rate was 90%, with
the highest rate (97%) reached in cirrhotic patients
treated with RBV, a the lowest (88%) in those treated
without RBV [35].
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Babatin et al. reported their real life experience in
treating 96 GT4 patients, 56 received SOF + SMV ± RBV
(group 1) whereas 40 SOF + DAC ± RBV for 12 weeks
(group 2). Liver cirrhosis was present in 53.6 and 35.0%
of group 1 and 2, respectively. Furthermore, 43.2% in
group 1 and 52.5% in group 2 already failed a previous
IFN-treatment. All patients achieved SVR 12 (100%
SVR), adverse events were reported in 32% of the pa-
tients but none discontinued treatment [36].
Special populations
Renal impairment
A recent multicenter trial investigated the efficacy
and safety of OBV/PTV/r and dasabuvir with/without
ribavirin in 35 GT1–4 HCV-infected patients under-
going hemodialysis [37]. In this difficult-to-treat
population, all patients archived SVR, without any
relevant safety concern. The most relevant side effect
was anemia, which was more marked in patients on
ribavirin (n = 17) and requiring increase of the dose
of erythropoiesis-stimulating agents. With specific ref-
erence to patients with renal impairment Ponziani et
al. also reported the outcomes of a series of 10 sub-
jects on hemodialysis therapy infected by GT1a, 1b,
or 4 HCV that received OBV/PTV/r (+ DSV in GT1),
with or without RBV [37]. All patients achieved
SVR12, and therapy was well tolerated.
The OBV/PTV/r regimen does not require dose modi-
fication for those with end-stage renal disease, with or
without dialysis.
End stage liver disease
The efficacy and safety of SOF/LDV association have
been also explored in patients with advanced cirrhosis in
Child-Pugh stage B or C in an open-label study con-
ducted at 34 sites in Europe [38]. Patients were ran-
domly assigned to 12 or 24 weeks of treatment with
SOF/LDV + RBV and were stratified in subgroups on the
basis of liver transplantation receipt or not and
Child-Pugh stage. Thirty-seven patients with HCV GT4
were enrolled and SVR was achieved in 30 subjects
(81%), with higher success rates in the groups treated for
24 weeks.
Discussion
The wide majority of clinical trials and ‘field-practice’ ex-
periences on HCV treatment are focused on GT1 and
GT3, which represent the most frequently-observed
genotype worldwide and the most challenging to
treat, respectively. Nevertheless, a large proportion of
patients is infected by GT4, but this population is
often under-represented in clinical trials. Moreover, in
the era of peg-IFN and RBV, GT4 was one of the
more difficult to treat genotypes, with SVR rates of
43–70% [38]. Therefore, many pre-treated patients, ei-
ther non-responders or relapsers, are still to be
treated in the current era.
On the other hand, data emerging from the analysis of
DAA-treated cohorts show an overall SVR rate > 90%,
even in the most difficult to cure populations such as
patients affected by liver cirrhosis. Available evidence on
GT4 therapy is overall scant. However, studies con-
ducted to date – both in the experimental and the
‘field-practice’ setting - have showed promising cure
rates up to 100%, even in treatment-experienced or cir-
rhotic GT4 patients, when administered for 12 weeks
courses. Very short treatments of only 6 or 8 weeks seem
not yet fully optimized, since also non-cirrhotic naïve
patients failed to reach satisfactory percentages of cure
in some contexts, even if the number of studied subjects
is still low [23]. In such scenario, the desire to spare a
few weeks of treatment risks may in turn be associated
with high risk of retreatment or onset of resistances.
Moreover, all DAAs appear very well tolerated, with dis-
continuation rates usually below 5%, and side effects
often linked more to RBV co-administration than to
DAA tolerability issues [27, 32].
Due to the period of analysis of the literature re-
view no more recent combinations have been in-
cluded. With these combinations the success rates
reach 97–99% success. This review is limited in being
tightly focused on effectiveness; as such, it does not
assess adverse reactions, quality of life, or any other
long-term factors [39–41].
The results of this analysis show the pivotal role of
OBV/PTV/r, which is characterized by a SVR rate higher
than 90% in all categories of patients [17, 27–30] and
studied for GT4 also in the context of advanced kidney
disease [35, 36]. Likewise SOF/LDV and SMV + SOF
achieve high success rates [11, 14–16, 21–26, 28, 34–
36]. We must also consider promising results obtained
with EBR +GZR [17, 32], glicaprevir/biprentasvir [19,
20, 42] and SOF/VEL in association or not with VOX
[8–11]. The data analysed in the present review clearly
show that there is not one regimen standing out com-
pared to others, but that there are many regimens that
can be safely used and that are effective for GT4 treat-
ment. An approach to GT4 treatment guided by current
guidelines is advisable [43–45], with continuous updat-
ing of the revolution of the therapeutic scenario cur-
rently underway.
Conclusions
The introduction of DAA therapy clearly revolutionized
the approach to treatment of HCV infection. Current
evidence shows high SVR rates and an excellent toler-
ability profile also in patients with GT4 infection, includ-
ing those with renal impairment. Although larger trials
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are needed to further confirm these findings, DAAs
grant the cure to thousands of patients and give them
a new hope to definitively clear HCV GT4 infection,
not only in newly infected patients, but also in who
underwent to IFN and RBV-related side effects and
failed to be cured.
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